ArticleTranslational vision science & technology2025
Improved IOL Power Calculation With Femtosecond Laser Enhanced Refractive Outcome Prediction.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to introduce and evaluate the femtosecond laser enhanced refractive outcome (FLERO) prediction method, an intraocular lens (IOL) calculator that augments Barrett Universal II (BUII) by integrating novel anterior segment optical coherence tomography (OCT) biometric predictors obtained during femtosecond laser-assisted cataract surgery (FLACS). Methods: Two thousand, three hundred sixty-three (2363) eyes of 1720 patients (mean age = 71.33 years, 60.26% women) undergoing FLACS were analyzed. FLERO was developed by selecting the most predictive subset of OCT-derived biometry features using a "genetic algorithm" and combining them with BUII predictions in a linear model. Internal validation was performed through cross-validation, and prediction errors (PEs) were compared with BUII and Kane errors. Results: Compared to BUII, FLERO increased the proportion of eyes achieving postoperative refraction within ±0.25 diopter (D), ±0.50 D, and ±1.00 D of target from 0.470 to 0.507, 0.781 to 0.824, and 0.962 to 0.970, respectively. Mean absolute error decreased from 0.345 D for BUII and 0.338 D for Kane to 0.315 D for FLERO. FLERO outperformed BUII and Kane across (short, medium, and long) eyes, where proportions of eyes achieving refraction within ±0.50 D were 0.696, 0.831, and 0.782 for FLERO, 0.468, 0.796, and 0.718 for BUII, and 0.595, 0.798, and 0.718 for Kane. Wilcoxon Signed-Rank testing indicated significant reductions in absolute PEs for FLERO versus BUII and Kane (P < 0.0001). PE regression revealed FLERO made significantly smaller errors. Conclusions: FLERO enhances BUII by incorporating novel OCT-derived FLACS biometric parameters across short, medium, and long eyes. Translational Relevance: FLERO combines advanced FLACS-derived intraoperative biometry with established IOL formulae to refine refractive outcome prediction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.